This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Chemotherapy-induced anemia (CIA) is a common complication in cancer patients receiving chemotherapy. The prevalence proportions of CIA and the severity of anemia vary by region, cancer type, and stage.
• All of the approved drugs for CIA target the erythropoietin receptor. These drugs are all administered via both the intravenous and subcutaneous routes.
• There are only two industry-sponsored drugs in active clinical development for CIA, both of which are in Phase III. Therapies in development for CIA focus on targets such as iron and hypoxia-inducible factor-prolyl hydroxylase. These drugs are administered via the intravenous and oral routes.
• The only high-impact upcoming event for drugs in the CIA space is topline Phase II/III trial results for roxadustat. The overall likelihood of approval of a Phase I marrow or peripheral blood stimulator asset is 23.7%, and the average probability a drug advances from Phase III is 82.5%. Drugs, on average, take 10.1 years from Phase I to approval, compared to 9.3 years in the overall hematology space.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for CIA have been in the late phases of development, with 61% of trials in Phase III–IV, and 39% in Phase I–II.
• Clinical trial activity in the CIA space is dominated by completed trials. Amgen has the highest number of completed clinical trials for CIA, with 67 trials.
• Amgen leads industry sponsors with the highest overall number of clinical trials for CIA, followed by Johnson & Johnson.